A comparison of drug sensitivity pattern in category-I failure versus category-I relapse pulmonary TB patients attending a tertiary care hospital in South Punjab, Pakistan. Is WHO category-II ATT regimen appropriate? Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Number of tuberculosis (TB) cases reported by primary care physicians (PCPs) in India: Results of a 1-day point prevalence study in 880 urban cities and towns in India Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management I Year: 2013
Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Study of prevalence of drug resistance in tuberculosis (TB) patients attending a tertiary care hospital at Mumbai Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis Year: 2016
Pattern of second line drug-resistance in MDR-TB treatment failure cases at a tertiary care tuberculosis treatment centre in western region of India Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Co-morbid conditions associated with tuberculosis (TB): Results from a 1-day, point-prevalence study in 204,912 physician diagnosed patients from 880 cities and towns in India Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management II Year: 2013
Frequency of rifampicin resistance in re-treatment cases of pulmonary tuberculosis using Gene-Xpert in a tertiary care hospital tuberculosis clinic Source: International Congress 2015 – WHO guidelines in TB and clinical practice Year: 2015
Case series of 83 XDR-TB patients in an urban hospital of Gujarat, India; an interim analysis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Programmatic management of drug resistance tuberculosis: Outcome analysis of 200 patients in western part of Rajasthan, India Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
High prevalence of hepatitis C among patients with drug-resistant tuberculosis and its impact on the treatment outcome in Azerbaijan prisons Source: International Congress 2015 – Screening strategies in TB Year: 2015
Centralization of M/XDR-TB care in clinical reference centres in Portugal. Experience of a regional reference centre Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
An analysis of mortality among patients with tuberculosis (TB) in Sri Lanka Source: Annual Congress 2011 - Tuberculosis epidemiology and public health Year: 2011
Active drug-safety monitoring and management for tuberculosis patients treated with bedaquiline and linezolid, Belarus – 2014-2016 Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Implementation of rapid drug-susceptibility testing for patients at high risk of multidrug-resistant tuberculosis in Cambodia Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013
National evidence on the inefficiency of an inpatient model of tuberculosis management in Eastern Europe Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations Year: 2013
Treatment outcome of 35 MDR TB patients with 2nd line drugs - a three year follow up report; Hyderabad, India Source: Eur Respir J 2005; 26: Suppl. 49, 651s Year: 2005
Childhood tuberculosis in Israel: epidemiological trends and treatment outcomes, 1999–2010 Source: Eur Respir J 2013; 41: 1157-1162 Year: 2013
Follow-up of TB cases failing or defaulting the first TB treatment, in Romania Source: Annual Congress 2012 - Non-tuberculous and tuberculous mycobacterial infections: from epidemiology to clinical findings Year: 2012
Patients over 35 years experience more side-effects during latent TB treatment: Experience from an urban hospital with a high incidence of Tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015